United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 10

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 10 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderElite Pharma · 50

Strongest available pathRhythm Pharmaceuticals · +712.6%

Widest latest marginFibroGen · 2848.6%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ELTP · OTC

Elite Pharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1998Alhambra, California$312.2M market cap

View full Companies Radar profile

50Moderate

Snapshot price$0.29as of page date

Monthly-close return+624.5%five-year window

FY2025 revenue$0.08BELITE PHARMACEUTICALS INC /NV/

Net margin-5.1%FY2025

P/E snapshot5.8xone ratio, not a verdict

Prism attention0.0%share across these five

Filing track recordRevenue, USD billions

+231.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 34.9%

52-week position4% through range

$0.27$0.72

News mentions2

Community mentions0partial coverage

U.S.-scope patents18

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal84/100
Management stability90/100
Market position3/100
Capital-event signal31/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2KYNB · Nasdaq

FibroGen

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1993San Francisco$31.5M market cap

View full Companies Radar profile

50Moderate

Snapshot price$7.78as of page date

Monthly-close return-97.0%five-year window

FY2025 revenue$0.01BKYNTRA BIO, INC.

Net margin2848.6%FY2025

P/E snapshot-0.5xone ratio, not a verdict

Prism attention24.9%share across these five

Filing track recordRevenue, USD billions

-97.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -59.3%

52-week position23% through range

$6.32$12.60

News mentions1.5K

Community mentions94partial coverage

U.S.-scope patents759

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal68/100
Management stability90/100
Market position3/100
Capital-event signal69/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3PTCT · Nasdaq

PTC Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1998South Plainfield, New Jersey$5.80B market cap

View full Companies Radar profile

49Cautious

Snapshot price$69.54as of page date

Monthly-close return+86.9%five-year window

FY2025 revenue$1.73BPTC THERAPEUTICS, INC.

Net margin39.4%FY2025

P/E snapshot27.8xone ratio, not a verdict

Prism attention43.7%share across these five

Filing track recordRevenue, USD billions

+221.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 33.9%

52-week position49% through range

$49.38$90.87

News mentions2.6K

Community mentions21partial coverage

U.S.-scope patents1963

Prism InsightsWhat sits behind the readiness signal
Observed risk 12/100higher means more observed risk

Earnings signal65/100
Management stability90/100
Market position10/100
Capital-event signal74/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 1 asset-acquisition events and 9 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 7 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4PAHC · Nasdaq

Phibro Animal Health

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2009Teaneck, New Jersey$1.53B market cap

View full Companies Radar profile

49Cautious

Snapshot price$37.74as of page date

Monthly-close return+75.2%five-year window

FY2025 revenue$1.30BPHIBRO ANIMAL HEALTH CORP

Net margin3.7%FY2025

P/E snapshot15.5xone ratio, not a verdict

Prism attention14.3%share across these five

Filing track recordRevenue, USD billions

+55.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 11.7%

52-week position30% through range

$28.25$60.08

News mentions859

Community mentions0partial coverage

U.S.-scope patents152

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal83/100
Management stability90/100
Market position21/100
Capital-event signal15/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 8 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5RYTM · Nasdaq

Rhythm Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Boston, Massachusetts$7.28B market cap

View full Companies Radar profile

49Cautious

Snapshot price$106.1as of page date

Monthly-close return+712.6%five-year window

FY2025 revenue$0.19BRHYTHM PHARMACEUTICALS, INC.

Net margin-103.6%FY2025

P/E snapshot-172.8xone ratio, not a verdict

Prism attention17.1%share across these five

Filing track recordRevenue, USD billions

+145.1%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 56.5%

52-week position66% through range

$74.50$122.2

News mentions1.0K

Community mentions21partial coverage

U.S.-scope patents193

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal71/100
Management stability90/100
Market position10/100
Capital-event signal55/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Rhythm Pharmaceuticals

+712.6%

Elite Pharma

+624.5%

PTC Therapeutics

+86.9%

Phibro Animal Health

+75.2%

FibroGen

-97.0%

Latest revenue

USD billions, official filing scope shown on each company card.

PTC Therapeutics

$1.73B

Phibro Animal Health

$1.30B

Rhythm Pharmaceuticals

$0.19B

Elite Pharma

$0.08B

FibroGen

$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

FibroGen

2848.6%

PTC Therapeutics

39.4%

Phibro Animal Health

3.7%

Elite Pharma

-5.1%

Rhythm Pharmaceuticals

-103.6%

Prism news attention

Normalized share across these five names; attention is not quality.

PTC Therapeutics

43.7%

FibroGen

24.9%

Rhythm Pharmaceuticals

17.1%

Phibro Animal Health

14.3%

Elite Pharma

0.0%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

PTC Therapeutics leads the conversation

It holds 43.7% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $1.73B.

Price path

Rhythm Pharmaceuticals leads the available price paths

Its monthly-close return is +712.6% for the five-year window. At the other end, FibroGen is -97.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

FibroGen has the widest latest margin

Its FY2025 net margin is 2848.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Rhythm Pharmaceuticals shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -172.8x while its five-year window price return is +712.6%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · KYNB

FibroGen

1,493available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-55.0%117 latest 12m vs 260 prior 12m

Machine-classified coverage tone

92.7% positive+1.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 14cancer biomarkers 12metastatic pancreatic survival 9angiogenesis inhibitors 9gene therapy rare diseases 9pancreatic adenocarcinoma prognosis 8cell-based therapies 6stock price 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-05-17–2026-06-02 · trend and themes shown through 2026-06

Areas of research · PTCT

PTC Therapeutics

2,613available Prism news records

Prism top themes

Price action & investor response

114

Capital allocation & transactions

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-21.5%332 latest 12m vs 423 prior 12m

Machine-classified coverage tone

90.4% positive+0.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 88orphan drug pricing 59rare disease treatment 51rare disease clinical trials 48orphan drug incentives 39orphan drug exclusivity 26company valuation 18stock price 15

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-19–2026-06-13 · trend and themes shown through 2026-06

Areas of research · PAHC

Phibro Animal Health

859available Prism news records

Prism top themes

Price action & investor response

132

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+58.8%270 latest 12m vs 170 prior 12m

Machine-classified coverage tone

89.1% positive-7.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 33stock performance 33share price 20earnings report 19vaccine formulation 17animal feed 15annual earnings 14animal vaccine efficacy 13

Keyword tag occurrences in available Prism news records.

Coverage: 2011-12-12–2026-06-18 · trend and themes shown through 2026-06

Areas of research · RYTM

Rhythm Pharmaceuticals

1,023available Prism news records

Prism top themes

Price action & investor response

105

Legal, arbitration & regulatory

Capital allocation & transactions

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+34.0%280 latest 12m vs 209 prior 12m

Machine-classified coverage tone

88.6% positive-3.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 40stock performance 24orphan drug pricing 20share price 13obesity pharmacotherapy 13market reaction 13semaglutide obesity 12orphan drug incentives 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-12–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

KYNB

FibroGen

94 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 94 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ELTP

Elite Pharma

through 2026-02-17

Earnings releases 17Leadership changes 2

2026-02-17
Earnings releases
Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million , an increase of $17.2 million or approximately 120% as compared to the comparable period of the prior fiscal year. Income from operations was $9.0 million , an increase of $7.9 million or approximately 721% , as compared to the comparable period of the prior fiscal year. Net income was $18.6 million.
2023-09-07
Leadership changes
today announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023.
2026-02-12
Earnings releases
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) (“Elite” or the “Company”), announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

KYNB

FibroGen

through 2025-08-11

Earnings releases 9Leadership changes 5Listing / IPO 2M&A 1

2025-08-11
Earnings releases
• FibroGen (NASDAQ:FGEN) is expected to report quarterly loss at $0.30 per share on revenue of $2.88 million.
2025-02-24
M&A
The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there.
2025-02-14
Listing / IPO
Fibrogen Inc., meanwhile, filed to raise up to $125 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PTCT

PTC Therapeutics

through 2026-04-17

Earnings releases 35Regulatory 25Leadership changes 15Company announcements 9Listing / IPO 4

2026-04-17
Regulatory
The inducement grant was approved by PTC's Compensation Committee on April 13, 2026, and is being made as an inducement material to the employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-03-25
Leadership changes
PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors.
2025-12-30
M&A
Royalty Pharma Plc (NASDAQ: RPRX) shares rose 1.5% in after-hours trading on Monday after the company announced it had acquired the final portion of PTC Therapeutics’ remaining royalty interest in Evrysdi, a leading spinal muscular atrophy (SMA) treatment marketed by Roche.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PAHC

Phibro Animal Health

through 2025-12-22

Earnings releases 15Leadership changes 9Asset acquisitions 5Company announcements 2Business contracts 1

2025-12-22
Leadership changes
Phibro Animal Health Corporation, a leading global diversified animal health and nutrition company based in Teaneck, announced that Daniel (Dani) Bendheim will become chief executive officer and president of Phibro.
2025-12-05
Earnings releases
In the quarter under review, net sales totaled $363.9 million, up 40% from the year-ago quarter’s level.
2025-10-09
Business contracts
Phibro Animal Health Corporation (Nasdaq: PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RYTM

Rhythm Pharmaceuticals

through 2026-03-31

Earnings releases 15M&A 3

2026-03-31
Earnings releases
The company had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million.
2026-01-28
M&A
State of Wyoming bought a new position in shares of Rhythm Pharmaceuticals in the second quarter valued at approximately $67,000.
2026-01-28
M&A
Bayforest Capital Ltd now owns 1,171 shares of the company’s stock worth $118,000 after acquiring an additional 1,055 shares during the period.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 46–53. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Elite Pharma leads the readiness ranking

Its Prism readiness score is 50/100, the highest in this five-company comparison.

Open Elite Pharma in Companies Radar

Scale and margin leadership sit with PTC Therapeutics and FibroGen

PTC Therapeutics has the largest displayed latest revenue at $1.73B; FibroGen has the widest displayed latest margin at 2848.6%.

Open PTC Therapeutics in Companies Radar Open FibroGen in Companies Radar

Comparisons

Strongest versus weakest available price path

Rhythm Pharmaceuticals is +712.6% for its five-year window; FibroGen is -97.0% for its five-year window.

Open Rhythm Pharmaceuticals in Companies Radar Open FibroGen in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $1.73B for PTC Therapeutics to $0.01B for FibroGen. Entity and filing-period labels remain visible on the company cards.

Open PTC Therapeutics in Companies Radar Open FibroGen in Companies Radar

Anomalies

Elite Pharma has the widest attention-readiness rank gap

It ranks #5 by measured news attention (0.0%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Elite Pharma in Companies Radar

Rhythm Pharmaceuticals shows a price-operating divergence to inspect

Its displayed filing-revenue change is +145.1% while its available monthly-close return is +712.6%. This is the basket's largest numerical spread; the measures use different units and windows and are not directly equivalent.

Open Rhythm Pharmaceuticals in Companies Radar

Explanations

Attention measures coverage volume, not quality

PTC Therapeutics's 43.7% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open PTC Therapeutics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Elite Pharma's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 50/100 score.

Open Elite Pharma in Companies Radar

Stress-test the largest divergence before forming a view

Compare Rhythm Pharmaceuticals's profile with Rhythm Pharmaceuticals's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Rhythm Pharmaceuticals in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.